CNBX PHARMACEUTICALS INC.: 10-K filed 2011-11-29
What CNBX PHARMACEUTICALS INC. reported in its annual report filed 2011-11-29 (fiscal FY 2011): 11 published measures, 21 facts as tagged in accession 0001303681-11-000207.
This filing
- Form
- 10-K (annual report)
- Filed
- 2011-11-29
- Fiscal period
- fiscal FY 2011
- Accession
- 0001303681-11-000207 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CNBX PHARMACEUTICALS INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2010-08-31 | 94,960 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-08-31 | -47,340 | USD | |
| At 2010-08-31 | 59,970 | USD | |
| At 2009-08-31 | 174,950 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2010-09-01 to 2011-08-31 | -107,310 | USD | 365 |
| 2004-09-15 to 2011-08-31 | -409,693 | USD | 2542 |
| 2009-09-01 to 2010-08-31 | -114,980 | USD | 365 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2004-09-15 to 2011-08-31 | -161,107 | USD | 2542 |
| 2009-09-01 to 2010-08-31 | 5,999 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2004-09-15 to 2011-08-31 | -199,788 | USD | 2542 |
| 2009-09-01 to 2010-08-31 | -183,740 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-08-31 | -409,693 | USD | |
| At 2010-08-31 | -302,383 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2004-09-15 to 2011-08-31 | 1,458 | USD | 2542 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-08-31 | 47,340 | USD | |
| At 2010-08-31 | 34,990 | USD |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-08-31 | 362,285 | USD | |
| At 2010-08-31 | 362,285 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2004-09-15 to 2011-08-31 | 11,130 | USD | 2542 |
| 2009-09-01 to 2010-08-31 | 2,180 | USD | 365 |
Proceeds from issuing common stock
Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2004-09-15 to 2011-08-31 | 360,895 | USD | 2542 |
Inspect the source
- Entity
- CNBX PHARMACEUTICALS INC. / CIK 0001343009
- Captured
- 2026-09-20T07:54:32.519Z
- SEC response SHA-256
915b78bb9f3d1ecdaff39577a9e5db4b6d0b32a87b795bd1dd92ab6d7b14ac19
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001343009.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))